Retrospective Study
Copyright ©The Author(s) 2016.
World J Transplant. Dec 24, 2016; 6(4): 712-718
Published online Dec 24, 2016. doi: 10.5500/wjt.v6.i4.712
Table 1 Baseline characteristics
DDKT (n = 111)SCD (32)AKI (51)ECD (28)aP-valuebP-value
Recipients
Age year (mean ± SD)42.7 ± 13.843.9 ± 12.043.1 ± 12.30.680.67
Male n (%)19 (59.4)35 (68.6)16 (57.1)0.480.55
Pre KT dialysis11
Hemodialysis n (%)26 (81.3)42 (82.4)23 (82.1)
Peritoneal dialysis n (%)6 (18.8)9 (17.7)5 (17.9)
Comorbid n (%)
DM2 (6.25)8 (15.7)3 (10.7)0.30.48
HT30 (93.8)49 (96.1)25 (89.3)0.670.41
CAD1 (3.1)1 (1.9)1 (3.6)11
Cause of ESRD n (%)0.910.73
Unknown (no biopsy)23 (23.2)33 (31.8)18 (18.9)
Diabetic nephropathy1 (0.9)1 (1.3)1 (0.8)
IgA nephropathy1 (1.9)2 (2.6)3 (1.5)
Chronic glomerulonephritis2 (0.9)1 (1.3)0 (0.8)
Blood group n (%)0.140.38
A4 (12.5)13 (25.5)7 (25.0)
B13 (40.6)13 (25.5)7 (25.0)
AB4 (12.5)2 (3.9)3 (10.7)
O11 (34.4)23 (45.1)11 (39.3)
PRA - % median (range)0 (0.85)0 (0.0)0 (0.0)0.030.04
Second KT n (%)2 (6.25)3 (5.88)1 (3.57)11
Total HLA mismatch - (mean ± SD)2.5 (1.2)2.3 (1.1)2.1 (1.1)0.520.76
Donors
Age, year (mean ± SD)33.9 ± 14.841.0 ± 12.061.2 ± 7.00.02< 0.001
Male n (%)24 (75.0)44 (86.3)17 (60.7)0.250.04
Terminal serum creatinine (mg/dL) - median (range)0.91 (0.73, 1.13)2.22 (1.65, 3.20)1.28 (0.99, 2.70)< 0.001
Cold ischemic time, minute (mean ± SD)1099 ± 2911129 ± 2941261 ± 2420.650.5
Immunosuppressive drugs
Induction n (%)0.110.19
No16 (50.0)16 (31.4)9 (32.1)
ATG5 (15.6)11 (21.6)11 (39.3)
Simulect11 (34.4)24 (47.1)8 (28.6)
Maintenance n (%)0.050.005
Tacrolimus/mycophenolate/prednisolone16 (50.0)27 (52.9)13 (46.4)
Cyclosporin A/mycophenolate/prednisolone15 (46.8)16 (31.4)5 (17.9)
Cyclosporin A/everolimus/prednisolone07 (13.7)8 (28.6)
Everolimus/mycophenolate/prednisolone1 (3.1)00